Health-Adjusted Life Expectancy among Canadian Adults with and without Hypertension by Loukine, Lidia et al.
SAGE-HindawiAccess to Research
Cardiology Research and Practice
Volume 2011, Article ID 612968, 7 pages
doi:10.4061/2011/612968
Research Article
Health-AdjustedLifeExpectancy amongCanadianAdultswith
andwithoutHypertension
LidiaLoukine,1 ChrisWaters,1 Bernar dC.K.Choi, 1,2,3 and Joellyn Ellison1
1Centre for Chronic Disease Prevention and Control, Public Health Agency of Canada (PHAC), Government of Canada,
Ottawa, ON, Canada K1A 0K9
2Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada
3Shantou University Medical College, Shantou 515041, China
Correspondence should be addressed to Bernard C. K. Choi, bernard.choi@phac-aspc.gc.ca
Received 19 October 2010; Accepted 11 April 2011
Academic Editor: Christina Chrysohoou
Copyright © 2011 Lidia Loukine et al.This is an open access article distributed under the Creative CommonsAttribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Hypertension can lead to cardiovascular diseases and other chronic conditions. While the impact of hypertension on premature
death and life expectancy has been published, the impact on health-adjusted life expectancy has not, and constitutes the research
objective of this study. Health-adjusted life expectancy (HALE) is the number of expected years of life equivalent to years lived
in full health. Data were obtained from the Canadian Chronic Disease Surveillance System (mortality data 2004–2006) and the
CanadianCommunityHealthSurvey (HealthUtilities Index data 2000–2005)forpeople with andwithouthypertension. Lifetable
analysis was applied to calculate life expectancy and health-adjusted life expectancy and their conﬁdence intervals. Our results
show that for Canadians 20 years of age, without hypertension, life expectancy is 65.4 years and 61.0 years, for females and males,
respectively. HALE is 55.0 years and 52.8 years for the two sexes at age 20; and 24.7 years and 22.9 years at age 55. For Canadians
with hypertension, HALE is only 48.9 years and 47.1 years for the two sexes at age 20; and 22.7 years and 20.2 years at age 55.
Hypertension is associated with a signiﬁcant loss in health-adjusted life expectancy compared to life expectancy.
1.Background
Hypertension or high blood pressure (HTN) is an important
risk factor for cardiovascular disease. In 2002, the World
HealthOrganizationestimated thatatleast50%ofcaseswith
cardiovascular disease and 75% of strokes were caused by
elevated blood pressure [1]. Hypertension is considered to
be one of the leading risk factors for death and disability
worldwide.
The number of Canadians with hypertension is increas-
ing in Canada. The ﬁrst report on hypertension from the
Canadian Chronic Disease Surveillance System published
by Public Health Agency of Canada shows that the age-
standardized prevalence of hypertension among the adult
population increased by about 7% between 1998 and 2006
and is projected to increase by another 25% by the end of
2012 [2]. According to that report the crude prevalence of
diagnosed hypertension among Canadian adults (20 years
old and older) in 2006 was 22.7%. Similar estimates of the
prevalence of hypertension are also reported by Statistics
Canada based on results from the ﬁrst cycle of Canadian
Health Measure Survey [3]. In many cases, the presence of
hypertension leads to premature death and therefore the
reduction of life expectancy (LE) and health expectancy
(healthy life expectancy). Because of high morbidity in the
hypertensive population, the reporting of mortality or life
expectancy which uses only mortality experience is not
enough to fully describe the burden of the chronic condition
in population.
This paper reports results on Health-Adjusted Life Ex-
pectancy (HALE). HALE is an indicator that can be used as
a summary measure of population health. While LE is the
averagenumber ofyears a person isexpected to live, HALEis
life expectancy weighted or adjusted for the level of Health
Related Quality of Life (HRQOL). It combines morbidity
and mortality data in one single indicator of population
health and indicates the average time that a person could
expect to live in a healthy state. Comparison of disparities2 Cardiology Research and Practice
in LE and HALE for a population of people with and with-
out hypertension, and evaluation of loss in LE and the pro-
portion of life lived in poor health for these cohorts can pro-
vide a comprehensive picture of how hypertension changes
the lives of people.
There are few published studies which looked at the
impact of hypertension on life expectancy [4, 5]a n d ,t oo u r
knowledge, no previously published study has looked at high
blood pressure and health expectancy. This is the ﬁrst pop-
ulation-based Canadian study of life expectancy and health-
adjusted life expectancy for people with and without diag-
nosed hypertension.
2.DataSourcesand Methods
Health-adjusted life expectancy is a composite indicator that
combines morbidity and mortality into a single statistic.
Mortality data ﬁles from the Canadian Chronic Disease
Surveillance System (CCDSS) were used for estimating
age and sex-speciﬁc mortality rates. While mortality data
and population counts are suﬃcient for calculating life
expectancy, a measure of health-related quality of life is
also needed to estimate health-adjusted life expectancy, its
variance and corresponding 95% conﬁdence intervals. The
measure used in this analysis was the Health Utilities Index
Mark 3 which was estimated from the Canadian Community
Health Survey (CCHS).
2.1. Canadian Chronic Disease Surveillance System. The Ca-
nadianChronicDiseaseSurveillanceSystemisacollaborative
network of provincial and territorial chronic disease surveil-
lance systems, supported by the Public Health Agency of
Canada [6]. It was created to improve the breadth of infor-
mation about the burden of chronic diseases in Canada so
that policy makers, researchers, health practitioners, and the
general public could make better public and personal health
decisions. CCDSS collects data from various sources on the
prevalence, incidence, mortality, and utilization of health
care services related to hypertension and other chronic con-
ditions and diseases.
In each province and territory, the health insurance reg-
istry database is linked to the physician billing and hospital-
ization databases to generate summarized data for residents
of Canada who have used the Canadian health care system.
These summarized data are stored in the CCDSSfor routine
analysis. If there is suﬃcient evidence of use due to hyper-
tension, it is assumed that a person had been diagnosed
with hypertension. The minimum requirement was at least
1 hospitalization or 2 physician claims over a 2-year period
with speciﬁc code(s)for hypertension from the International
ClassiﬁcationofDiseases(ICD)(ICD-9codes401–405;ICD-
10codesI10–I13 and I15).Withrespect to hypertension, the
CCDSScollects data for the adult populationonly, that is, 20
years old and older.
ForCanadianadultswithandwithouthypertension, age-
speciﬁc mortality rates for all causes are included in the
CCDSS. For this study, the age-speciﬁc mortality rates for
persons with and without adult hypertension were used to
calculate life expectancy and health-adjusted life expectancy.
The study was limited to persons who are 20 years old and
older.
2.2. Canadian Community Health Survey. The Canadian
Community Health Survey is an ongoing cross-sectional
national health survey, conducted by Statistics Canada [7–
9], that collects information related to health status, health
care utilization, and health determinants for the Canadian
population. It includes a large sample of about 130,000
respondents and is designed to provide reliable estimates at
the local health region level.
Prior to 2007, data collection occurred every 2 years for
a 12-month period. After major changes to the survey design
in2007,datacollectionnowoccursonanongoing(monthly)
basis with annual releases. Data are available for 2000/2001,
2003, 2005, 2007, 2008, and 2009.
The CCHS produces an annual microdata ﬁle and a ﬁle
combining 2 years of data. The survey collection years can
also be combined by users to examine subpopulations of
rare characteristics. The respondents of the ﬁrst three cycles
of the survey were asked if they have any of 26–30 chronic
conditions including hypertension. The survey data include
information for persons aged 12 years and older. The survey
does not include people who live in institutions or in remote
areas. The household-level response rate in 2005 was 84.9%,
and the person-level response rate was 92.5% [9].
As a measure of health-related quality of life, the Health
Utilities Index Mark 3 from the following three CCHS data
ﬁles was used for this study: (1) cycle1.1 2000/2001share ﬁle
[7]; (2) cycle 2.1 2003 subsample 1 ﬁle [8]; and (3) cycle 3.1
2005 subsample 1 ﬁle [9].
2.3. Health Utilities Index Mark 3. HUI3 is a multiattribute
utility measure that deﬁnes health states according to eight
attributes (vision, hearing, speech, ambulation, dexterity,
emotion, cognition, and pain), with ﬁve or six levels ranging
from normal to severely limited functioning for each.
Single attribute utility scores range from 0.0 (lowest level
of functioning) to 1.0 (full functional capacity) [10]. The
eight attributes are combined into a single score using the
multiattribute utility function:
u = 1.371 ∗ (b1 ∗ b2 ∗ b3 ∗ b4 ∗ b5 ∗ b6 ∗ b7 ∗ b8) − 0.371,
(1)
where u is HUI3 and bi is a single attribute utility score.
The overall scores on the HUI3 range from −0.36 (the
worst possible HUI3 health state), through 0.0 (death), to
1.0 (perfect health). From a societal perspective, some health
states are considered worse than dead, and consequently
are assigned negative scores. Diﬀerences of 0.03 or more in
overall HUI3 scores and 0.05 or more in single-attribute
utility scores are considered to be clinically important [11].
Sex and age-speciﬁc HUI averages were estimated from
ac o m b i n e dC C H Sd a t aﬁ l ef o rp e r s o n sw i t ha n dw i t h o u t
hypertension. The bootstrap methodology [12], recom-
mended by Statistics Canada, was used to calculate the var-
iance estimate. Boththepoint estimatesand variance estima-
tionswerecalculatedusingtheBOOTVARE V31macro[13].Cardiology Research and Practice 3
2.4. Survey Sample Sizes. All three cycles of the CCHS (cycle
1.1 share ﬁle, cycle 2.1 subsample, and cycle 3.1 subsample)
were combined by the pooled method to increase the sample
size and to decrease variation in the estimates [14]. The
sample size for the combined ﬁle, which included people 20
years and older and spanned the years 2000 through 2005,
was 173,567 (32,612 with hypertension; 140,955 without
hypertension).
Mortality datafor Quebecand Nunavutwere unavailable
from the CCDSS, and health utilities index data from the
Northwest Territories and Nunavut were unavailable from
the 2000/2001 CCHS (cycle 1.1) survey ﬁle. Therefore, these
jurisdictions were excluded from all analyses.
2.5. Life Table Analysis. The Chiang method [15]w a su s e d
to generate period (2004–2006) life tables by disease-
speciﬁc/disease-deleted populations and by sex using the 14
standard agegroups(20–24,25–9,...,80–85,85+years). The
Gompertz function was used to provide an accurate estimate
of life expectancy for the last open-ended 85+ age interval,
in order to close the life table. This method was described by
Hsieh [16]. The modiﬁed Sullivan method [17] was applied
for the HALE calculation. According to this method the “life
years lived” was adjusted by the HUI
L 
x = Lx ∗ HUIx,( 2 )
where L 
x is adjusted life years lived in age interval x, Lx is
life years lived in age interval x,a n dH U I x is Health Utilities
index for people in age interval x.
The variance ofLE was calculatedby the Chiang method.
The variance in HALE,for the populationwithout hyperten-
sion, was calculated by the Bebbington method [18]t a k i n g
into account just the variability of HUI. The sample size
of the population without hypertension was large; therefore
the variance of the life-table itself was close to zero and did
not contribute much to the variance of HALE. However, the
sample size of population with hypertension was relatively
small and the life-table variance was quite noticeable and
could not be ignored. Therefore the variance of HALE
for the population with hypertension was calculated taking
into account both the variability of the life table and the
variability of HUI. This method was introduced by Mathers
[19]. All calculations were performed using specially devel-
oped SAS macros. The 95% conﬁdence intervals for LE and
HALE were built based on the normality assumption. Z-
tests were used to test the statistical signiﬁcance of loss in
life expectancy and the absolute diﬀerence in life expectancy.
The absolute diﬀerence in life expectancy is deﬁned as the
diﬀerence between life expectancy and the health adjusted
life expectancy (LE-HALE) for the same cohort.
3.Results
Figures 1 and 2 show age and sex-speciﬁc estimates of the
total (LE) and the healthy (HALE) number of years of life
remaining for adults without and with hypertension. As
expected,highervaluesforboth LEand HALEwere obtained
Table 1: Diﬀerence in life expectancy (LE) and health-adjusted life
expectancy (HALE) between females and males with and without
hypertension (HTN) for selected ages, Canada, 2004 to 2006.
(Dataset for this study excluded Quebec, Nunavut and Northwest
Territories.)
LE(F)-LE(M) HALE(F)-HALE(M)
At age of 20 years
With HTN 5.2∗ 1.8∗∗
Without HTN 4.4∗ 2.2∗
At age of 55 years
With HTN 4.2∗ 2.5∗
Without HTN 3.6∗ 1.8∗
At age of 85 years
With HTN 2.0 0.9
Without HTN 1.7 0.8
∗Statisticallysigniﬁcant (P-value < .0001).
∗∗Statisticallysigniﬁcant (P-value < .05).
for people not diagnosed and who did not report hyperten-
sion. For 20-year-old females who were not diagnosed with
hypertension, LE was estimated to be an additional 65.4
years and HALE was an additional 55 years (Figure 1). The
corresponding LE and HALE for males were 61.0 and 52.8
years, respectively. Within the population of people with
hypertension, the LE and HALE were, respectively, 62.1 and
48.9 years for females and 56.9 and 47.1 years for males
(Figure 2).
Figure 3 illustrates diﬀerences in age- and sex-speciﬁc
average Health Utilities Index for persons with and with-
out hypertension. HUI reported by men was higher than
that reported by women for both populations. The index
decreased with age and was lower for persons with disease.
The diﬀerence in LE between female and male popu-
lations with hypertension varies between 2.0 and 5.2 years
across agegroups,higherthanthatinthepopulationwithout
hypertension (Table 1). Diﬀerences in HALE between sexes
were approximately half the diﬀerence in LE. HALE diﬀer-
ences between females and males with hypertension were
between 0.9 and 2.5 years. Similar patterns were observed
for persons without hypertension. The narrower diﬀerence
in HALE was a result of men reporting better health (higher
HUI score) than women. Many LE and HALE diﬀerences
reported in Table 1 were statistically signiﬁcant.
Table 2 illustrates absolute and relative measures of
unhealthy years of life as well as the loss in LE and HALE
associated with hypertension within age-sex grouping. The
age groups selected for presentation were, the beginning of
l i f et a b l e( a g e2 0y e a r s ) ,t h ea v e r a g ea g eo fh y p e r t e n s i o n
incidence (55 years), and the last age interval of the life table
(85 years). As age increases, the number of unhealthy years
of life decreases while the proportion of unhealthy life years
remaining increases. The unhealthy years of life for persons
with hypertension varied between 13.2 years (at age 20) and
3.6 years (at age 85+) for females and between 9.8 years
(at age 20) and 2.5 years (at age 85+) for males which was
much higher than that for persons without hypertension.
The corresponding number of unhealthy years for person4 Cardiology Research and Practice
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Figure 1: Life expectancy (LE) and health adjusted life expectancy (HALE) for females and males, without hypertension, Canada, 2004
to 2006. (Data source: Canadian Community Health Survey Data Files (CCHS) from Statistics Canada, 2000–2005 and Canadian Chronic
Disease Surveillance System Data Files (CCDSS) from Public Health Agency of Canada, 2004–2006. Data Files excluded Quebec, Nunavut
and Northwest Territories.)
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Figure 2: Lifeexpectancy (LE) and health adjusted life expectancy (HALE) forfemales and males,with hypertension, Canada,2004 to 2006.
(Data source: Canadian community health survey data ﬁles (CCHS) from Statistics Canada, 2000–2005 and Canadian Chronic Disease
Surveillance System Data Files (CCDSS) from Public Health Agency of Canada, 2004–2006. Data Files excluded Quebec, Nunavut and
Northwest Territories.)
without hypertension was in a range 10.4–3.4 years for
females and 8.2–2.5 years for males. When people without
hypertension were compared to those with hypertension the
loss in both LE and HALE decreased with increasing age for
both women and men. The loss in LE decreased from 3.3
y e a r sa ta g e2 0y e a r sd o w nt o0 . 1y e a r sa ta g e8 5f o rw o m e n
and from 4.1 down to 0.4 years for men. The loss in HALE
decreases from 6.1 years at age 20 down to 0.3 years at age
85 for women and from 5.7 down to 0.4 years for men.
All absolute diﬀerences were statistically signiﬁcant (P-value
< .0001) for all age groups except 85+ age group. (It was
not possible to calculate the signiﬁcance level for the 85+ age
group.)
4.Discussion
In this study LE and HALE were estimated for Canadian
adults (20 years old and older) with and without diagnosed
hypertension by sex and fourteen 5-year age intervals. Our
results show that life expectancy decreases with increasing
age and that the decline is faster for LE than HALE (Figures
1 and 2). To explain this observation the age gradient in HUICardiology Research and Practice 5
0.500
0.550
0.600
0.650
0.700
0.750
0.800
0.850
0.900
0.950
H
e
a
l
t
h
 
u
t
i
l
i
t
i
e
s
 
i
n
d
e
x
 
m
a
r
k
 
3
without HBP, females 0.897 0.912 0.895 0.908 0.895 0.87 0.866 0.861 0.846 0.851 0.83 0.768 0.707 0.607
without HBP, males 0.904 0.918 0.916 0.913 0.899 0.894 0.874 0.876 0.862 0.866 0.851 0.802 0.741 0.639
with HBP, females 0.812 0.893 0.772 0.839 0.785 0.822 0.79 0.805 0.819 0.816 0.791 0.740 0.703 0.572
with HBP, males 0.812 0.882 0.885 0.851 0.866 0.869 0.842 0.817 0.83 0.816 0.818 0.767 0.696 0.61
85+
Age (years)
20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84
Figure 3: Health utilities index (HUI) for females and males with and without hypertension (HTN), Canada, 2000 to 2005. (Data source:
Canadian Community Health Survey Data Files (CCHS) from Statistics Canada, 2000–2005. Dataset for this study excluded Quebec,
Nunavut and Northwest Territories.)
scores and mortality rates was compared, which revealed, as
age increased, mortality rates increased faster than the HUI
scores declined.Our results also conﬁrm that, in Canada, the
LE for females is higher than for males, a direct result of
higher mortality among men. It is also true for the popu-
lation of people with hypertension (Table 1).
I tw a sobs erv edth a tagr ea t ern um berofy ea r soflif ew er e
l o s ti nH A L Et h a ni nL Ee s p e c i a l l ya ty o u n g e ra g e s( T a b l e2).
Hypertension impacts on health and body functions to
a greater extent than it impacts on mortality among young
people. Diﬀerences in LE and HALE for people who was
aged 85 years or older were very small and similar for both
men and women. Presence or absence of hypertension at
this advanced age only slightly impacted longevity and the
estimated loss in life was very small.
The results attribute signiﬁcant loss of health expectancy
to hypertension. In reality, hypertension is a convenient
marker which functions as a surrogate for health risks not
controlled for in the analysis. Future work should target
controlling for risk factors concurrent with a diagnosis of
hypertension.That kindofstudycouldquantifythepotential
impact of prevention of obesity, smoking, physical inactivity,
and other risk factors associated with population health.
Moredetaileddata wouldberequired. Forinstance mortality
rates by BMI class would be required to evaluate the eﬀect
obesityonpopulationhealth.Workplanshavebeenprepared
to explore the feasibility of controlling for obesity in HALE
estimation.
The absolutediﬀerencebetweenLEandHALErepresents
the number of years a person spends in poor health. Relative
diﬀerencesbetweenLEandHALEquantifytheportionoflife
apersonspendsinpoorhealth.Thatis,theratioofunhealthy
yearstothelifeexpectancy((LE-HALE)/LE).Thesemeasures
are only meaningful within the same population (i.e., for
the population of people of the same age with or without
hypertension). Both measures were greater for populations
of people with hypertension than for people without the
disease (Table 2). Women spent more years and a greater
portion of life in poor health than did men. It was observed
that the number of unhealthy years decreased and the
portion of life a person spends in poor health increased with
increasing age. This was true for both sexes and for both
diseased and not diseased populations. For example, at age
20 years, women with hypertension spent 21% of their
remaining lives in poor health and that percentage gradually
increased to 42% by age 85. This age gradient in relative
diﬀerences varied from 16% up to 40% for women without
hypertension. The samepatternwasobservedformenaswell
but the proportions were smaller. Women with hypertension
lived shorter lives and spend an even greater portion of their
lives in poor health than did women without hypertension.
Diﬀerences in LE associated with hypertension were
estimated for people in eastern Finland using a baseline
age of 25 years by Kiiskinen et al. [4]. The loss in LE of
2.7 years for men and 2.2 years for women were reported.
These estimates were lower than our estimates (3.7 men, 2.8
women, derived from Figures 1 and 2), but consistent in that
the loss in life was larger for males than for females. Direct
comparability with our results was hampered by diﬀerences
in methodology, data used, reporting year, and character-
istics of the populations studied. Our literature search did
not identify any publicationquantifying diﬀerencesin HALE
associated with hypertension.6 Cardiology Research and Practice
Table 2: Life expectancy (LE), health-adjusted life expectancy (HALE) (With 95% Conﬁdence Intervals), and Loss of LE and HALE at
selected ages,byhypertension (HTN)statusandsex,Canada,2004to2006.(Datasetforthisstudyexcluded Quebec, NunavutandNorthwest
Territories.)
Sex Life expectancy measure Without HTN (I) With HTN (II) Loss of life expectancy associated
with HTN (I-II)
At age 20 years
Females
LE 65.4 (65.3-65.4) 62.1 (61.9–62.4) 3.3∗
HALE 55.0 (54.6–55.3) 48.9 (48.1–49.7) 6.1∗
LE-HALE 10.4∗ 13.2∗
(LE-HALE)/LE 0.16 0.21
Males
LE 61.0 (61.0-61.0) 56.9 (56.7–57.2) 4.1∗
HALE 52.8 (52.5–53.1) 47.1 (46.3–47.8) 5.7∗
LE-HALE 8.2∗ 9.8∗
(LE-HALE)/LE 0.13 0.17
At age 55 years
Females
LE 31.6 (31.6-31.7) 30.1 (30.1-30.2) 1.5∗
HALE 24.7 (24.4–25.1) 22.7 (22.3–23.0) 2.0∗
LE-HALE 6.9∗ 7.4∗
(LE-HALE)/LE 0.22 0.25
Males
LE 28.0 (28.0-28.1) 25.9 (25.8-25.9) 2.1∗
HALE 22.9 (22.6–23.2) 20.2 (19.8–20.6) 2.7∗
LE-HALE 5.1∗ 5.7∗
(LE-HALE)/LE 0.18 0.22
At age 85 years
Females
LE 8.6 8.5 0.1
HALE 5.2 4.9 0.3
LE-HALE 3.4 3.6
(LE-HALE)/LE 0.40 0.42
Males
LE 6.9 6.5 0.4
HALE 4.4 4.0 0.4
LE-HALE 2.5 2.5
(LE-HALE)/LE 0.36 0.38
∗Statisticallysigniﬁcant at .05.
A limitation of our study was that data for residents of
long-term care facilities were not available for calculation
of our estimates of life expectancy and health-adjusted life
expectancy. As a result, the true values for the entire popula-
tion would be somewhat lower than what we reported. It is
also important to note that misclassiﬁcation of hypertension
status is present in both the survey data and the surveillance
system data we used. In the Canadian Community Health
Survey, misclassiﬁcation can be due to self-reporting bias, a
tendency to underreport the true disease status. In the Cana-
dian Chronic Disease Surveillance System, misclassiﬁcation
can be present in geographic areas where complete data
are not available. Areas with a larger proportion of salaried
physicians provide the least complete data, which results in
identifying fewer individuals with disease. Consequently, the
disease status concordance between the two data sources
varies by province and territory [20–22]. Future linkage of
these two data sources (CCDSS and CCHS) would reduce
self-reporting bias and misclassiﬁcation error. The estimates
of LE and HALE presented in this paper are based on
mortality and morbidity experience of people with and
without hypertension for the period of 2004–2006. They
should be treated as descriptive cross-sectional statistics
based on past experience rather than predictive, as the mor-
tality and morbidity experience will change with time.
This paper described the method used by the Public
Health Agency of Canada to calculate life expectancy and
health-adjusted life expectancy among Canadian adults with
and without hypertension, based on mortality data for
2004 to 2006 and morbidity data for 2000 to 2005. Our
work shows that it is possible to calculate health-adjusted
life expectancy for all Canadians and for subpopulationsCardiology Research and Practice 7
with this particular chronic condition. Our method can be
adapted for calculations for other chronic conditions and
diseases to provide useful information for public health
researchers and policy makers.
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